Malignant hyperthermia is a rare pharmacogenetic disorder of skeletal muscles. It occurs after subjection to potent volatile anaesthetics, succinylcholine and environmental agents like heat and strenuous exercise. Symptoms of malignant hyperthermia are variable based on age and the common symptoms being hyperthermia, tachycardia and hypercarbia. Dantrolene is the universal treatment of choice. The main aim of this case presentation was to highlight the successful management of malignant hyperthermia without the use of dantrolene. This was a case report of a one year and eleven months old baby who presented thirteen months post facial burn with hypertrophic scars, ectropion and contractures of the mouth. The patient was scheduled for contracture release of the mouth and ectropion repair. Intraoperatively, she had symptoms of suspected malignant hyperthermia such as hyperthermia (38.9°C), hypercarbia (PETCO2> 55) and tachycardia (heart rate 202bpm). Dantrolene the drug of choice was available but had expired. Supportive care was initiated and patient managed successfully. The patient was extubated on the table uneventfully, taken to recovery and transferred to the wards afterwards. She recovered fully without any sequale of hyper metabolic crisis post operatively and was discharged home after two weeks. This case report illustrates that early recognition of malignant hyperthermia is the key to improved patient survival. Aggressive supportive care can lead to good outcomes even in the absence of the drug dantrolene.
| Published in | International Journal of Medical Case Reports (Volume 1, Issue 4) |
| DOI | 10.11648/j.ijmcr.20220104.13 |
| Page(s) | 45-49 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Malignant Hyperthermia, Hypercabia, Volatile Anaesthetics, Pharmacogenetic, Capnograph
| [1] | H. Rosenberg, M. Davis, D. James, N. Pollock, and K. Stowell, “Malignant hyperthermia.,” Orphanet J. Rare Dis., vol. 2, p. 21, Apr. 2007, doi: 10.1186/1750-1172-2-21. |
| [2] | T. F. G. Barbosa, A. Machado, I. A. Correia, and A. C. Sá, “Malignant hyperthermia: a case report with good outcome,” Porto Biomed. J., vol. 6, no. 1, 2021. |
| [3] | C. Ball, “Unravelling the mystery of malignant hyperthermia.,” Anaesth. Intensive Care, vol. 35 Suppl 1, pp. 26–31, Jun. 2007, doi: 10.1177/0310057X0703501s05. |
| [4] | M. A. Denborough, J. F. A. Forster, R. R. H. Lovell, P. A. Maplestone, and J. D. Vllliers, “Anesthetic deaths in a family,” 1960. |
| [5] | S. W. Yoo, S. J. Baek, D.-C. Kim, and A. R. Doo, “A case report of malignant hyperthermia in a patient with myotonic dystrophy type I: A CARE-compliant article.,” Medicine (Baltimore)., vol. 100, no. 23, p. e25859, Jun. 2021, doi: 10.1097/MD.0000000000025859. |
| [6] | MAUS (Malignant Hyperthamia association of the United States), “What is the Incidence of MH?” https://www.mhaus.org/faqs/what-is-the-incidence-of-mh/. |
| [7] | H. Jadoon, “Malignant hyperthermia: survival without dantrolene–a case report,” Anaesthesia, Pain Intensive Care, 2019. |
| [8] | M. G. Larach, B. W. Brandom, G. C. Allen, G. A. Gronert, and E. B. Lehman, “Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: a report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States.,” Anesthesiology, vol. 108, no. 4, pp. 603–611, Apr. 2008, doi: 10.1097/ALN.0b013e318167aee2. |
| [9] | R. S. Litman and H. Rosenberg, “Malignant hyperthermia: update on susceptibility testing.,” JAMA, vol. 293, no. 23, pp. 2918–2924, Jun. 2005, doi: 10.1001/jama.293.23.2918. |
| [10] | D. Chamley, N. A. Pollock, K. M. Stowell, and R. L. Brown, “Malignant hyperthermia in infancy and identification of novel RYR1 mutation,” Br. J. Anaesth., vol. 84, no. 4, pp. 500–504, 2000. |
| [11] | R. H, S. N, and et al. Riazi S, “Malignant Hyperthermia Susceptibility Summary Genetic counseling,” GeneReviews®, 2020, [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK1146/. |
| [12] | H. Rosenberg, N. Pollock, A. Schiemann, T. Bulger, and K. Stowell, “Malignant hyperthermia: a review,” Orphanet J. Rare Dis., vol. 10, p. 93, Aug. 2015, doi: 10.1186/s13023-015-0310-1. |
| [13] | V. S. Pillai, R. C. Koshy, M. Balakrishnan, and R. Ramakrishnan, “Malignant hyperthermia in India: Time for awakening, useful facts on Dantrolene,” Egypt. J. Anaesth., vol. 31, no. 1, pp. 81–83, 2015, doi: https://doi.org/10.1016/j.egja.2014.09.002. |
| [14] | M. G. Larach et al., “A clinical grading scale to predict malignant hyperthermia susceptibility.,” Anesthesiology, vol. 80, no. 4, pp. 771–779, Apr. 1994, doi: 10.1097/00000542-199404000-00008. |
| [15] | A. Iqbal, S. Badoo, and R. Naqeeb, “A case report of suspected malignant hyperthermia where patient survived the episode.,” Saudi journal of anaesthesia, vol. 11, no. 2. pp. 232–235, 2017, doi: 10.4103/1658-354X.203057. |
| [16] | I. Kaddoura, G. Abu-Sittah, A. Ibrahim, R. Karamanoukian, and N. Papazian, “Burn injury: review of pathophysiology and therapeutic modalities in major burns.,” Ann. Burns Fire Disasters, vol. 30, no. 2, pp. 95–102, Jun. 2017. |
| [17] | W. R. Simmons DO, D. Feng MD, Z. Ma MD, X. Gu MD, and J. Huang, “MH Survival without Dantrolene,” 2020. |
| [18] | I. S.-M. Acosta, G. V. de Cos, and M. T. Fernández, “Malignant Hyperthermia Syndrome: A Clinical Case Report.,” EJIFCC, vol. 32, no. 2. pp. 286–291, Jun. 2021. |
APA Style
Belinda Namisi, Betty Owure. (2022). Suspected Malignant Hyperthermia in a Child with Post-Facial Burn Hypertrophic Scars and Ectropion: A Case Report at Kenyatta National Hospital. International Journal of Medical Case Reports, 1(4), 45-49. https://doi.org/10.11648/j.ijmcr.20220104.13
ACS Style
Belinda Namisi; Betty Owure. Suspected Malignant Hyperthermia in a Child with Post-Facial Burn Hypertrophic Scars and Ectropion: A Case Report at Kenyatta National Hospital. Int. J. Med. Case Rep. 2022, 1(4), 45-49. doi: 10.11648/j.ijmcr.20220104.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijmcr.20220104.13,
author = {Belinda Namisi and Betty Owure},
title = {Suspected Malignant Hyperthermia in a Child with Post-Facial Burn Hypertrophic Scars and Ectropion: A Case Report at Kenyatta National Hospital},
journal = {International Journal of Medical Case Reports},
volume = {1},
number = {4},
pages = {45-49},
doi = {10.11648/j.ijmcr.20220104.13},
url = {https://doi.org/10.11648/j.ijmcr.20220104.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijmcr.20220104.13},
abstract = {Malignant hyperthermia is a rare pharmacogenetic disorder of skeletal muscles. It occurs after subjection to potent volatile anaesthetics, succinylcholine and environmental agents like heat and strenuous exercise. Symptoms of malignant hyperthermia are variable based on age and the common symptoms being hyperthermia, tachycardia and hypercarbia. Dantrolene is the universal treatment of choice. The main aim of this case presentation was to highlight the successful management of malignant hyperthermia without the use of dantrolene. This was a case report of a one year and eleven months old baby who presented thirteen months post facial burn with hypertrophic scars, ectropion and contractures of the mouth. The patient was scheduled for contracture release of the mouth and ectropion repair. Intraoperatively, she had symptoms of suspected malignant hyperthermia such as hyperthermia (38.9°C), hypercarbia (PETCO2> 55) and tachycardia (heart rate 202bpm). Dantrolene the drug of choice was available but had expired. Supportive care was initiated and patient managed successfully. The patient was extubated on the table uneventfully, taken to recovery and transferred to the wards afterwards. She recovered fully without any sequale of hyper metabolic crisis post operatively and was discharged home after two weeks. This case report illustrates that early recognition of malignant hyperthermia is the key to improved patient survival. Aggressive supportive care can lead to good outcomes even in the absence of the drug dantrolene.},
year = {2022}
}
TY - JOUR T1 - Suspected Malignant Hyperthermia in a Child with Post-Facial Burn Hypertrophic Scars and Ectropion: A Case Report at Kenyatta National Hospital AU - Belinda Namisi AU - Betty Owure Y1 - 2022/12/27 PY - 2022 N1 - https://doi.org/10.11648/j.ijmcr.20220104.13 DO - 10.11648/j.ijmcr.20220104.13 T2 - International Journal of Medical Case Reports JF - International Journal of Medical Case Reports JO - International Journal of Medical Case Reports SP - 45 EP - 49 PB - Science Publishing Group SN - 2994-7049 UR - https://doi.org/10.11648/j.ijmcr.20220104.13 AB - Malignant hyperthermia is a rare pharmacogenetic disorder of skeletal muscles. It occurs after subjection to potent volatile anaesthetics, succinylcholine and environmental agents like heat and strenuous exercise. Symptoms of malignant hyperthermia are variable based on age and the common symptoms being hyperthermia, tachycardia and hypercarbia. Dantrolene is the universal treatment of choice. The main aim of this case presentation was to highlight the successful management of malignant hyperthermia without the use of dantrolene. This was a case report of a one year and eleven months old baby who presented thirteen months post facial burn with hypertrophic scars, ectropion and contractures of the mouth. The patient was scheduled for contracture release of the mouth and ectropion repair. Intraoperatively, she had symptoms of suspected malignant hyperthermia such as hyperthermia (38.9°C), hypercarbia (PETCO2> 55) and tachycardia (heart rate 202bpm). Dantrolene the drug of choice was available but had expired. Supportive care was initiated and patient managed successfully. The patient was extubated on the table uneventfully, taken to recovery and transferred to the wards afterwards. She recovered fully without any sequale of hyper metabolic crisis post operatively and was discharged home after two weeks. This case report illustrates that early recognition of malignant hyperthermia is the key to improved patient survival. Aggressive supportive care can lead to good outcomes even in the absence of the drug dantrolene. VL - 1 IS - 4 ER -
Information
Email: